Meerpohl H G
Onkologie. 1984 May;7 Suppl 2:22-34. doi: 10.1159/000215512.
The role of chemotherapy in the management of carcinoma of the ovary is becoming increasingly important. It is the first-line treatment of choice in all patients with stage III or IV of disease and where tumor deposits larger than 2 cm remain in the abdominal cavity after surgery. Until recently the main drugs have been used to treat ovarian cancer are the alkylating agents. In addition to these agents three new active drugs - hexamethylmelamine, adriamycin, cis-platinum - have been studied and their potential role is more carefully defined. Today the definition and better understanding of prognostic criteria play a primary role in the selection of treatment drugs. With continued efforts to define optimum treatment modalities and by application of some of the new treatment ideas coming from the laboratory, perhaps the poor survival of patients with ovarian epithelial malignancies will be further improved.
化疗在卵巢癌治疗中的作用正变得越来越重要。对于所有处于疾病Ⅲ期或Ⅳ期以及术后腹腔内仍有大于2 cm肿瘤残留的患者，化疗是首选的一线治疗方法。直到最近，用于治疗卵巢癌的主要药物一直是烷化剂。除了这些药物外，三种新的活性药物——六甲蜜胺、阿霉素、顺铂——已得到研究，并且它们的潜在作用得到了更确切的界定。如今，对预后标准的界定和更好理解在治疗药物的选择中起着主要作用。随着不断努力去确定最佳治疗方式，并应用一些来自实验室的新治疗理念，或许卵巢上皮性恶性肿瘤患者较差的生存率将会得到进一步改善。
